Renal transplantation in anti-neutrophil cytoplasmic antibody-associated vasculitis

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F15%3A10295093" target="_blank" >RIV/00216208:11110/15:10295093 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064165:_____/15:10295093

Výsledek na webu

<a href="http://dx.doi.org/10.1093/ndt/gfu328" target="_blank" >http://dx.doi.org/10.1093/ndt/gfu328</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1093/ndt/gfu328" target="_blank" >10.1093/ndt/gfu328</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Renal transplantation in anti-neutrophil cytoplasmic antibody-associated vasculitis

Popis výsledku v původním jazyce

Despite major advances in the management of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) achieved in the last decades, a large proportion of AAV patients still develop end-stage renal disease. The survival of AAV patients dependent on dialysis is significantly worse compared with dialysis-independent AAV patients, but is comparable to other non-diabetic patients requiring dialysis. Renal transplantation (RTx) is the method of choice among renal replacement therapies and there has been increasing evidence that it is a suitable method with favorable patient- and graft-survival also in AAV patients. It is recommended to perform RTx after a parts per thousand yen12 months of remission, and ANCA positivity at the time of RTx isgenerally not considered a contraindication. Even though the risk of relapse after RTx is relatively low with current post-transplant immunosuppressive regimens, disease recurrence may occur. Besides cyclophosphamide, rituximab might beco

Název v anglickém jazyce

Renal transplantation in anti-neutrophil cytoplasmic antibody-associated vasculitis

Popis výsledku anglicky

Despite major advances in the management of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) achieved in the last decades, a large proportion of AAV patients still develop end-stage renal disease. The survival of AAV patients dependent on dialysis is significantly worse compared with dialysis-independent AAV patients, but is comparable to other non-diabetic patients requiring dialysis. Renal transplantation (RTx) is the method of choice among renal replacement therapies and there has been increasing evidence that it is a suitable method with favorable patient- and graft-survival also in AAV patients. It is recommended to perform RTx after a parts per thousand yen12 months of remission, and ANCA positivity at the time of RTx isgenerally not considered a contraindication. Even though the risk of relapse after RTx is relatively low with current post-transplant immunosuppressive regimens, disease recurrence may occur. Besides cyclophosphamide, rituximab might beco

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FE - Ostatní obory vnitřního lékařství

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Nephrology Dialysis Transplantation

ISSN

0931-0509

e-ISSN

—

Svazek periodika

30

Číslo periodika v rámci svazku

Supplement 1

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

5

Strana od-do

"i159"-"i163"

Kód UT WoS článku

000353500300023

EID výsledku v databázi Scopus

2-s2.0-84926640643